Edison Issues Initiation on Arix Bioscience (ARIX)

Tuesday, April 18, 2017 Drug News
Email Print This Page Comment
Font : A-A+

LONDON, April 18, 2017 /PRNewswire/ --

We are initiating coverage on Arix Bioscience following its February

2017 IPO that raised £113m. Arix is a new transatlantic life sciences portfolio company drawing from managerial expertise at all levels of the pharma industry to engage in opportunities ranging from seed investing to public equity. It draws on
a network of deal sources established through agreements with academia, life science accelerators, other funds, and through partnerships with big pharma. The company is trading at a modest 11% premium to our initial asset valuation of £172m or 179p/share.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

Using a risk-adjusted NPV analysis, we arrive at a valuation of Arix's assets (£133.2m cash, £27.3m portfolio, £11.4m other assets) of £172m or 179p/share. The value of the portfolio is nearly 100% above the cash spent to date (£13.7m). The stock trades at an 11% premium to this value, which is modest considering the strength of the company's management and platform, as well as the quality of the deals. We expect to update our valuation with the announcement of new deals.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

http://www.edisoninvestmentresearch.com

About Edison:  

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details:

Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn http://www.linkedin.com/company/edison-investment-research

Twitter http://www.twitter.com/Edison_Inv_Res

YouTube http://www.youtube.com/edisonitv

Google+ https://plus.google.com/105425025202328783163/posts

For more information please contact: Nathaniel Calloway Edison Investment Research +1-646-653-7036

Maxim Jacobs Edison Investment Research +1-646-653-7027 healthcare@edisongroup.com

SOURCE Edison Investment Research



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook